A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19
To estimate the efficacy, safety, tolerability and reactogenicity of 2 IM doses of AZD1222 compared to placebo for the prevention of COVID-19 in adults. To see if you qualify for the study, please visit this webpage: http://bit.ly/covid19vaccinestudy
This Study is
No Longer Enrolling
Adult
III - Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.
Treatment
National
Greeley Campus
Medical Center of the Rockies
Poudre Valley Hospital
Protocol Number: 20-9990
More information available at ClinicalTrials.gov: NCT04516746
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers